Alembic Pharmaceuticals cash flow

Latest FY26

Cash from operations: ₹783cr+789.8% on FY25
Capital spending: ₹435cr−22.9% on FY25
Free cash flow: ₹348cr−₹476 cr in FY25
Cash from financing: −₹164cr₹444 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	319	0.0	273	275
	—	93.6	78.8	56.2	50.2
	—	−0.9	−6.0	−2.1	−0.3
	—	−0.4	−1.1	−1.6	−0.6
	—	0.8	−0.4	−2.8	−0.1
	—	16.3	24.3	−40.2	29.1
	—	21.5	0.2	3.7	103
	—	−223	−645	−168	134
	—	7.7	−395	39.1	−223
	—	0.4	16.4	−9.3	14.7
	—	−51.2	−65.4	−8.3	112
	—	−49.3	146	56.0	−28.2
	—	5.3	−8.4	24.0	−42.1
	—	4.0	6.9	−25.6	−42.1
	—	0.0	279	0.0	0.0
	—	25.3	20.6	−4.8	6.4
	—	23.4	2.0	1.5	9.7
Cash from operating activities
	725	694	706	633	386
	—	193	−547	190	399
	—	886	159	823	785
	—	104	71.4	19.9	60.7
	—	783	88.0	803	724
Cash from investing activities
	—	435	564	327	443
	—	2.2	9.8	11.6	1.9
	—	60.3	0.0	0.0	0.0
	—	0.0	5.0	0.0	7.0
	—	0.0	16.1	8.3	0.0
	—	0.4	1.1	1.6	0.6
	—	0.7	5.5	2.0	0.3
	—	−14.5	0.0	0.0	0.0
	—	−506	−568	−321	−448
Cash from financing activities
	—	165	765	0.0	206
	—	0.0	0.0	205	200
	—	24.4	26.6	0.0	23.1
	—	—	—	25.8	0.0
	—	88.1	78.6	49.4	49.7
	—	216	216	157	197
	—	−0.3	−0.0	−0.0	1.5
	—	−164	444	−438	−262
	—	113	−36.7	44.7	14.4
	—	0.0	0.0	0.0	0.0
	—	113	−36.7	44.7	14.4
	—	—	83.5	120	75.5
Reference items
	1,169	1,118	1,008	933	708
	15.0%	15.2%	15.1%	15.0%	12.5%
	348	348	−476	476	281
	—	425	211	221	—
	₹17.71	₹17.71	−₹24.20	₹24.20	₹14.27
	44.88×	—	—	—	—
	—	1.17×	0.15×	1.30×	2.12×
	—	104	71.4	19.9	60.7
	—	88.1	78.6	49.4	49.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,623 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	275.4	272.7	0.0	318.6	—
+ Finance Costs	50.2	56.2	78.8	93.6	—
+ Interest Income	-0.3	-2.1	-6.0	-0.9	—
+ Dividend Income	-0.6	-1.6	-1.1	-0.4	—
+ Fair Value (Gains) / Losses	-0.1	-2.8	-0.4	0.8	—
+ Unrealised FX (Gain) / Loss	29.1	-40.2	24.3	16.3	—
+ Other Non-cash Items	103.1	3.7	0.2	21.5	—
Changes in Working Capital
+ Inventories	134.4	-168.3	-644.6	-222.5	—
+ Trade Receivables — Current	-222.9	39.1	-395.0	7.7	—
+ Other Financial Assets — Current	14.7	-9.3	16.4	0.4	—
+ Other Current Assets	112.4	-8.3	-65.4	-51.2	—
+ Trade Payables — Current	-28.2	56.0	146.2	-49.3	—
+ Other Financial Liabilities — Current	-42.1	24.0	-8.4	5.3	—
+ Other Current Liabilities	-42.1	-25.6	6.9	4.0	—
+ Other Non-current Liabilities	0.0	0.0	278.6	0.0	—
+ Provisions — Current	6.4	-4.8	20.6	25.3	—
+ Provisions — Non-current	9.7	1.5	2.0	23.4	—
Cash from Operating Activities
Profit Before Tax (per I/S)	385.5	632.8	706.3	693.7	724.6
+ Total Adjustments (incl. Working Capital)	399.1	190.2	-546.9	192.7	—
Cash from Operations (pre-tax)	784.6	823.1	159.4	886.4	—
+ Income Taxes Paid	60.7	19.9	71.4	103.7	—
Cash from Operating Activities	723.9	803.2	88.0	782.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	443.4	327.5	563.6	434.6	—
+ Disp of Fixed Assets	1.9	11.6	9.8	2.2	—
+ Acq of Intangibles under Development	0.0	0.0	0.0	60.3	—
+ Acq of Other Long-term Assets	7.0	0.0	5.0	0.0	—
+ Purchase of Investments (Equity / Debt)	0.0	8.3	16.1	0.0	—
+ Dividends Received — Investing	0.6	1.6	1.1	0.4	—
+ Interest Received — Investing	0.3	2.0	5.5	0.7	—
+ Other Inflows / (Outflows) — Investing	0.0	0.0	0.0	-14.5	—
Cash from Investing Activities	-447.6	-320.6	-568.4	-506.1	—
Cash from Financing Activities
+ Proceeds from Borrowings	205.9	0.0	765.1	165.3	—
+ Repayment of Borrowings	200.0	205.4	0.0	0.0	—
+ Payment of Lease Liabilities	23.1	0.0	26.6	24.4	—
+ Payment of Finance Lease Liabilities	0.0	25.8	—	—	—
+ Interest Paid	49.7	49.4	78.6	88.1	—
+ Dividends Paid	196.6	157.3	216.2	216.2	—
+ Other Inflows / (Outflows) — Financing	1.5	-0.0	-0.0	-0.3	—
Cash from Financing Activities	-262.0	-437.9	443.7	-163.8	—
Net Changes in Cash (pre-FX)	14.4	44.7	-36.7	112.9	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	0.0	0.0	—
Net Changes in Cash	14.4	44.7	-36.7	112.9	—
Closing Cash	75.5	120.2	83.5	—	—
Reference Items
EBITDA	708.4	933.4	1,008.2	1,118.5	1,169.0
EBITDA Margin %	12.53	14.98	15.11	15.23	15.02
Free Cash Flow (CFO − Capex)	280.5	475.7	-475.7	348.1	348.1
Free Cash Flow to Equity	—	220.9	210.9	425.3	—
Free Cash Flow per Basic Share	14.27	24.20	-24.20	17.71	17.71
Price to Free Cash Flow	—	—	—	—	44.88
Cash Flow to Net Income	2.12	1.30	0.15	1.17	—
Cash Paid for Taxes	60.7	19.9	71.4	103.7	—
Cash Paid for Interest	49.7	49.4	78.6	88.1	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.